Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 12
Submit an article Journal homepage
26
Views
5
CrossRef citations to date
0
Altmetric
Review

Cancer gene therapy: developments to 2000

Andrew R Bateman Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA. [email protected]
,
Kevin J Harrington Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA. [email protected]
,
Alan A Melcher Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA. [email protected]
&
Richard G Vile Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA. [email protected]
Pages 2799-2813 | Published online: 23 Feb 2005

Bibliography

  • SAUNDERS M, DISCHE S, BARRETT A, HARVEY A, GRIFFITHS G, PALMAR M: Continuous, hyperfraction-ated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother. Oncol. (1999) 52:137–148.
  • MCGUIRE WP, HOSKINS WJ, BRADY MF et al.: Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage W ovarian cancer: a Gynecologic Oncology Group study. Semin. Oncol. (1997) 24:S2-13-S12–16.
  • Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet (1992) 339:71–85.
  • Systemic treatment of early breast cancer byhormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet (1992) 3 39:1–15.
  • ROTH JA, NGUYEN D, LAWRENCE DD et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. (1996) 2:985–991.
  • SCHULER M, ROCHLITZ C, HOROWITZ JA et al: A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. (1998) 9:2075–2082.
  • SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1999) 91:763–771.
  • CLAYMAN GL, FRANK DK, BRUSO PA, GOEPFERT H: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. (1999) 5:1715–1722.
  • WEBB A, CUNNINGHAM D, COTTER F et al: BCL-2antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137–1141.
  • TAIT DL, OBERMILLER PS, HATMAKER AR, REDLIN-FRAZIER S, HOLT JT: Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. (1999) 5:1708–1714.
  • CUNNINGHAM CC, HOLMLUND JT, SCHILLER JH et al: A Phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. (2000) 6:1626–1631.
  • TURNER PC: Ribozymes. Their design and use in cancer. Adv. Exp. Med. Biol. (2000) 465:303–318.
  • MARCUSSON EG, YACYSHYN BR, SHANAHAN WR, JR., DEAN NM: Preclinical and clinical pharmacology of an tisense oligonucleo tides. MoL BiotechnoL (1999) 12:1–11.
  • COTTER FE: Antisense therapy of hematologic malignancies. Semin. Hematol. (1999) 36:9–14.
  • MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
  • SPRINGER CJ, NICULESCU-DUVAZ I: Prodrug-activatingsystems in suicide gene therapy. J. Clin. Invest. (2000) 105:1161–1167.
  • FREEMAN SM: Suicide gene therapy. Adv. Exp. Med. Biol.(2000) 465:411–422.
  • MOOLTEN FL: Drug sensitivity 'suicide' genes forselective cancer chemotherapy. Cancer Gene Ther. (1994) 1:279–287.
  • FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274–5283.
  • VILE RG, NELSON JA, CASTLEDEN S, CHONG H, HART IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves animmune component. Cancer Res. (1 9 9 4)54:6228-6234.
  • GAGANDEEP S, BREW R, GREEN B et al: Prodrug-activated gene therapy: involvement of an immuno-logical component in the 'bystander effect'. Cancer Gene Ther. (1996) 3:83–88.
  • RAM Z, CULVER KW, OSHIRO EM et al: Therapy ofmalignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. (1997) 3:1354–1361.
  • •First report of a suicide gene therapy clinical trial.
  • KLATZMANN D, CHERIN P, BENSIMON G et al: A PhaseI/II dose-escalation study of herp es simplex virus Type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther. (1998) 9:2585–2594.
  • KLATZMANN D, VALERY CA, BENSIMON G et al.: A PhaseI/II study of herpes simplex virus Type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblas-toma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. (1998) 9:2595–2604.
  • SHAND N, WEBER F, MARIANI L et al: A Phase I - IIclinical trial of gene therapy for recurrent glioblas-toma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10:2325–2335.
  • STERMAN DH, TREAT J, LITZKY LA et al: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. (1998) 9:1083–1092.
  • VILE RG, RUSSELL SJ, LEMOINE NR: Cancer gene therapy:hard lessons and new courses. Gene Ther. (2000) 7:2–8.
  • VAN DER EB MM, CRAMER SJ, VERGOUWE Y et al.: Severehepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. (1998) 5:451–458.
  • KOKORIS M, SABO P, BLACK M: In vitro evaluation ofmutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. (2000) 20:959–964.
  • AGHI M, KRAMM CM, CHOU TC, BREAKEFIELD XO, CHIOCCA EA: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/ cytosine deaminase gene therapies. J. Natl. Cancer Inst. (1998) 90:370–380.
  • ROGULSKI KR, ZHANG K, KOLOZSVARY A, KIM JH, FREYTAG SO: Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin. Cancer Res. (1997) 3:2081–2088.
  • HANNA NN, MAUCERI HJ, WAYNE JD, HALLAHAN DE,KUFE DW, WEICHSELBAUM RR: Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. (1997) 57:4205–4209.
  • PEDERSON LC, BUCHSBAUM DJ, VICKERS SM et al: Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. (1997) 57:4325–4332.
  • KAWASHITA Y, OHTSURU A, KANEDA Y et al: Regres-sion of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. (1999) 10:1509–1519.
  • LAMBIN P, NUYTS S, LANDUYT W et al: The potentialtherapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Intl RadiaL Biol. (2000) 76:285–293.
  • BATEMAN A, BULLOUGH F, MURPHY S et al: Fusogenicmembrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. (2000) 60:1492–1497.
  • DIAZ RM, BATEMAN AR, EMILIUSEN L et al: A Izntiviralvector expressing a fusogenic membrane glycopro-tein for cancer gene therapy. Gene Ther. (2000). (In Press).
  • SPITZWEG C, ZHANG S, BERGERT ER et al.: Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. (1999) 59:2136–2141.
  • MELCHER A, TODRYK S, HARDWICK N, FORD M, JACOBSON M, VILE RG: Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. (1998) 4:581–587.
  • •A significant report detailing the importance of the mechanism of cell death in tumour immunogenicity.
  • MELCHER A, GOUGH M, TODRYK S, VILER: Apoptosis ornecrosis for tumor immunotherapy: what's in a name? J. Mot. Med. (1999) 77:824–833.
  • MATZINGER P: An innate sense of danger. Semin.Immunol. (1998) 10:399–415.
  • •A review of the 'danger' model.
  • MATZINGER P: Tolerance, danger and the extendedfamily. Ann. Rev. Immunol. (1994) 12:991–1045.
  • TODRYK S, MELCHER AA, HARDWICK N et al.: Heat shockprotein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol (1999) 163:1398–1408.
  • TAMURA Y, PENG P, LIU K, DAOU M, SRIVASTAVA PK:Irnmunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278:117–120.
  • DAVIS ID: An overview of cancer immunotherapy. Immunol. Cell Biol. (2000) 78:179–195.
  • SELIGER B, MAEURER MJ, FERRONE S: TAP off tumors on. Immunol. Today (1997) 18:292–299.
  • HSIEH CL, CHEN DS, HWANG LH: Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. (2000) 11 :681–692.
  • HAHNE M, RIMOLDI D, SCHROTER M et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implica-tions for tumor immune escape. Science (1996) 274:1363–1366.
  • DIAZ R, VILE R: Molecular Immunotherapy by gene transfer. In: Blood Cell Biochemistry (Volume 8):Hematopoiesis and Gene Therapy Fairbairn LJ, Testa N (Eds.), Kluwer Academic/Plenum, New York, USA (1999) 8:331–350.
  • BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
  • •A review of the key role played by dendritic cells in initiating an immune response.
  • GALLUCCI S, LOLKEMA M, MATZINGER P: Natural adjuvants: endogenous activators of dendritic cells. Nature Med. (1999) 5:1249–1255.
  • ZLOTNIK A, YOSHIE 0: Chemokines: a new classifica- tion system and their role in immunity. Immunity (2000) 12:121–127.
  • •A detailed review of this important family.
  • CYSTER JG: Chemokines and cell migration in secondary lymphoid organs. Science (1999) 286:2098–2102.
  • FUSHIMI T, KOJIMA A, MOORE MA, CRYSTAL RG: Macrophage inflammatory protein 3a transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. j Clin. Invest. (2000) 105:1383–1393.
  • •The first report of the use of chemokines in cancer gene therapy.
  • SHURIN MR, ESCHE C, LOTZE MT: FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. (1998) 9:37–48.
  • MARASKOVSKY E, BRASEL K, TEEPE M et al.: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Merl. (1996) 184:1953–1962.
  • •The first report detailing the profound effect Flt-3 ligand has on DC numbers in vivo.
  • LYNCH DH, ANDREASEN A, MARASKOVSKY E, WHITMORE J, MILLER RE, SCHUH JC: F1t3 ligand induces tumor regression and antitumor immune responses in viva Nature Merl. (1997) 3:625–631.
  • CHAKRAVARTY PK, ALFIERI A, THOMAS EK et al.: Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. (1999) 59:6028–6032.
  • CHEN K, BRAUN S, LYMAN S et al: Antitumor activityand immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. (1997) 57:3511–3516.
  • WARREN TL, WEINER GJ: Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. (2000) 7:168–173.
  • DRANOFF G, JAFFEE E, LAZENBY A et al: Vaccinationwith irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539–3543.
  • •A significant report comparing cytokine efficacy in a murine vaccination protocol.
  • SOIFFER R, LYNCH T, MIHM M et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent an immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95:13141–13146.
  • •A detailed report of a clinical vaccination trial involving an autologous tumour vaccine secreting GM-CSF.
  • SIMONS JW, MIKHAK B, CHANG JF et al: Induction ofimmunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160–5168.
  • KAYAGA J, SOUBERBIELLE BE, SHEIKH N et al.:Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allo gen eic tumour cell vaccine. Gene Ther. (1999) 6:1475–1481 A significant report regarding allogeneic vaccines. KIRK CJ, MULE JJ: Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther. (2000) 11:797-806. DALGLEISH AG: Cancer vaccines. Br. J. Cancer (2000) 82:1619-1624. MELERO I, VILE RG, COLOMBO MP: Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther. (2000) 7:1167–1170.
  • FONG L, ENGLEMAN EG: Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. (2000) 18:245–273.
  • KLEIN C, BUELER H, MULLIGAN RC: Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. (2000) 191:1699–1708.
  • NAIR SK, HEISER A, BOCZKOWSKI D et al.: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Merl. (2000) 6:1011–1017.
  • GONG J, CHEN D, KASHIWABA M, KUFE D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Merl. (1997) 3:558–561.
  • •A paper indicating the potential of DC-tumour hybrids.
  • CELLUZZI CM, FALO LD, JR.: Physical interactionbetween dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. (1998) 160:3081–3085.
  • LESPAGNARD L, METTENS P, VERHEYDEN AM et al: Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer (1998) 76:250–258.
  • WANG J, SAFFOLD S, CAO X, KRAUSS J, CHEN W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. (1998) 161:5516–5524.
  • KUGLER A, STUHLER G, WALDEN P et al.: Regression of human metastatic renal cell carcinoma after vaccina-tion with tumor cell-dendritic cell hybrids. Nature Med. (2000) 6:332–336.
  • ••Clinical study using a DC-tumour hybrid vaccine.
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
  • ••An excellent overview of the molecular biology of cancer.
  • HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353–364.
  • DESAI SB, LIBUTTI SK: Tumor angiogenesis and endothelial cell modulatory factors. J. Immunother. (1999) 22:186–211.
  • HARRIS SR, THORGEIRSSON UP: Tumor angiogenesis: biology and therapeutic prospects. In Vivo (1998) 12:563–570.
  • BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284:808–812.
  • BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404–407.
  • •A significant report highlighting the potential of targeting tumour vasculature.
  • GOLDMAN CK, KENDALL RL, CABRERA G et al.: Par acrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate. Proc. Natl. Acad. ScL USA (1998) 95:8795–8800.
  • UN P, BUXTON JA, ACHESON A et al: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA (1998) 95:8829–8834.
  • TANAKA T, MANOME Y, WEN P, KUFE DW, FINE HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med. (1997) 3:437–442.
  • LI H, GRISCELLI F, LINDENMEYER F et al: Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. (1999) 10:3045–3053.
  • SAUTER By, MARTINET 0, ZHANG WJ, MANDELI J, WOOSL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. ScL USA (2000) 97:4802–4807.
  • NGUYEN JT, WU P, CLOUSE ME, HLATKY L, TERWILLIGER EF: Aden o-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. (1998) 58:5673–5677.
  • WEISSMAN IL: Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science (2000) 287:1442–1446.
  • ASAHARA T, MUROHARA T, SULLIVAN A et al: Isolation of putative progenitor endothelial cells for angiogene-sis. Science (1997) 27 5:964–967.
  • SHI Q, RAFII S, WU MH et al: Evidence for circulating bone marrow-derived endothelial cells. Blood (1998) 92:362–367.
  • GOMEZ-NAVARRO J, CONTRERAS JL, ARAFAT W et al: Genetically modified CD34 + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther. (2000) 7:43–52.
  • •An interesting study indicating the potential of endothelial progenitors as delivery vehicles.
  • CHANG S, SEYMOUR L: Gene therapy scrutiny: the duality of delivery. Curr. Opin. Mol. Ther. (2000) 2:129–130.
  • Gene therapy - a loss of innocence. Nature Med. (2000)6:1.
  • KRASNYKH VN, DOUGLAS JT, VAN BEUSECHEM VW: Genetic targeting of adenoviral vectors. Mol. Ther. (2000) 1:391–405.
  • WICKHAM TJ: Targeting adenovirus. Gene Ther. (2000) 7:110–114.
  • PENG KW, RUSSELL SJ: Viral vector targeting. Curr. Opin. Biotechnol. (1999) 10:454–457.
  • BROOKES DE, ZANDVLIET D, WATT F, RUSSELL PJ, MOLLOY PL: Relative activity and specificity of promoters from prostate-expressed genes. Prostate (1998) 35:18–26.
  • STEINER MS, ZHANG Y, CARRAHER J, LU Y: In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther. (1999) 6:456–464.
  • HORIKAWA I, CABLE PL, AFSHARI C, BARRETT JC:Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. (1999) 59:826–830.
  • TAKAKURA M, KYO S, KANAYA T et al.: Cloning of human telomerase catalytic subunit (h IIRT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. (1999) 59:551–557.
  • SHAY JW: Telomerase in cancer: diagnostic, prognostic and therapeutic implications. Cancer./ ScL Am. (1998) 4 (Suppl. 1):S26–34.
  • BUYS CH: Telomeres, telomerase and cancer. N Engl. J. Med. (2000) 342:1282–1283.
  • RIVERA VM, CLACKSON T, NATESAN S et al.: A humanized system for pharmacologic control of gene expression. Nature Med. (1996) 2:1028–1032.
  • •The first report detailing the development and efficacy of the rapamycin system.
  • YE X, RIVERA VM, ZOLTICK P et al.: Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 283:88–91.
  • HALLAHAN DE, MAUCERI HJ, SEUNG LP etal.: Spatial and temporal control of gene therapy using ionizing radiation. Nature Med. (1995) 1:786–791.
  • CHUNG TD, MAUCERI HJ, HALLAHAN DE et al: Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. (1998) 5:344–349.
  • RUSSELL SJ: Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur. J. Cancer (1994) 8:1165-1171. PENG K-W, VILER: Vector development for cancer gene therapy. Tumour Targeting (1999) 4:3-11. PENNISI E: Training viruses to attack cancers. Science (1998) 282:1244-1246. HALL AR, DIX BR, O'CARROLL SJ, BRAITHWAITE AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. (1998) 4:1068–1072.
  • HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an El B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. (1997) 3:639–645.
  • •A significant report detailing the preclinical development of ONYX-015.
  • KHURI FR, NEMUNAITIS J, GANLY I et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Merl. (2000) 6:879–885.
  • ••The first clinical trial report combining ONYX-015 andchemotherapy.
  • ANDERSON WF: Gene therapy scores against cancer. Nature Merl. (2000) 6:862–863.
  • HERMISTON T: Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. (2000) 105:1169–1172.
  • WILDNER 0, BLAESE RM, MORRIS JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. (1999) 59:410–413.
  • ROGULSKI KR, WING MS, PAIELLI DL, GILBERT JD, KIM JH, FREYTAG SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. (2000) 11:67–76.
  • MCCART JA, PUHLMANN M, LEE J et al.: Complex interac-tions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. (2000) 7:1217–1223.
  • HALLENBECK PL, CHANG YN, HAY C et al.: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. (1999) 10:1721–1733.
  • RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication-competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559–2563.
  • YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59:4200–4203.
  • MARTUZA RL: Conditionally replicating herpes vectors for cancer therapy. J. Clin. Invest. (2000) 105:841–846.
  • RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7:859–866.
  • MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7:867–874.
  • KIRN DH: A tale of two trials: selectively replicating herpesviruses for brain tumors. Gene Ther. (2000) 7:815–816.
  • PAWLIK TM, NAKAMURA H, YOON SS et al.: On coly sis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. (2000) 60:2790–2795.
  • COFFEY MC, STRONG JE, FORSYTH PA, LEE PW: Reovirus therapy of tumors with activated Ras pathway. Science (1998) 282:1332–1334.
  • STOJDL DF, LICHTY B, KNOWLES S et al: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Merl. (2000) 6:821–825.

Websites

  • http://seer.cancer.gov/Publications/CSR 191973_1997/ overview
  • http://www4.od.nih.gov/oba/clinicaltrial.htm

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.